NEWRON PHARMACEUT. EO-20 Cash Flow Reinvestment Rate

Latest as of December 2025: 0.42x

NEWRON PHARMACEUT. EO-20 cash flow reinvestment rate. NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Reinvestment Rate of 0.42x as of December 2025, reinvesting €13.66 Million (capex €48.00K plus investments €-13.62 Million) from operating cash flow of €32.35 Million. Explore NEWRON PHARMACEUT. EO-20 debt service capacity to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.42x

(Capex + Investments) / Operating CF

Total Reinvested

€13.66 Million

Capex + Investments

Operating Cash Flow

€32.35 Million

EUR

Capital Expenditures

€48.00K

EUR

Cash Flow Reinvestment Rate of NEWRON PHARMACEUT. EO-20 (2025–2025)

Cash flow reinvestment rate of NEWRON PHARMACEUT. EO-20 from 2025 to 2025. Historical reinvestment intensity for NEWRON PHARMACEUT. EO-20 across 1 annual periods. Explore NEWRON PHARMACEUT. EO-20 (NP5) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

NEWRON PHARMACEUT. EO-20 Cash Flow Reinvestment Rate by Year (2025–2025)

NEWRON PHARMACEUT. EO-20 cash flow reinvestment rate by year from 2025 to 2025. Year-by-year capital reinvestment analysis for NEWRON PHARMACEUT. EO-20. For the full cash flow conversion analysis, see NP5 cash generation efficiency.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2025	0.42x	€13.66 Million	€32.35 Million	€48.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow